Latest Macula Stories
The eating disorder anorexia nervosa causes potentially serious eye damage.
LEUVEN, Belgium, September 6, 2010 /PRNewswire-FirstCall/ -- - Data Presented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were...
LEUVEN, Belgium, September 1, 2010 /PRNewswire-FirstCall/ -- - Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of...
Seahorses are helping scientists gain new understanding about how detailed vision develops â€“ in research which may open a way to restore sight in people with age-related blinding diseases.
SARATOGA, Calif., July 6 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the U.S. Food and Drug Administration (FDA) has approved the company's Implantable Miniature Telescope (by Dr.
SUNNYVALE, Calif., May 4 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it will present an abstract demonstrating the utility of its Verisome(TM) Liquid Drug Delivery System in cystoid macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2010 annual meeting, taking place May 2-6, 2010, in Fort Lauderdale,...
ST. LOUIS, May 4 /PRNewswire/ -- ZeaVision, LLC introduced Eye-Q(TM), an intelligent AMD Risk Management program for EyeCare Professionals and patients to manage a key risk factor for Age-related Macular Degeneration (AMD).
Ranibizumab injections plus laser therapy results in dramatic visual improvement.
Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.
Despite the fact that crowding affects more than ninety-five per cent of the visual field, we know very little about how it occurs, aside from the fact that it happens not in the eye, but in parts of the brain that deal with seeing.
- To swell, as grain or wood with water.
More Images (2 images) »